| Source: |
| Type: |
| Gut microbiome may affect responses to numerous forms of cancer therapy. The gut microbiota plays a multifaceted role in cancer biology, influencing tumor development, progression, and patient prognosis. Dysbiosis and specific microbial populations have been linked to various cancers, with implications for patient outcomes. While the relationship between gut microbiota and cancer prognosis is an active area of research, it holds promise for the development of microbiome-based biomarkers and therapeutic strategies in oncology. |
| 1161- | ACNs, | immuno, | Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota |
| - | in-vivo, | Colon, | MC38 |
| 541- | Akk, | Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes? |
| - | Review, | Var, | NA |
| 540- | Akk, | Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy |
| - | Analysis, | Var, | NA |
| 4- | Akk, | The Emerging Biotherapeutic Agent: Akkermansia |
| - | Review, | Var, | NA |
| 5351- | Akk, | Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut |
| - | Human, | Diabetic, | NA |
| 5421- | ASTX, | Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice |
| - | in-vivo, | Pca, | NA |
| 4982- | ATV, | Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer |
| - | in-vivo, | Ovarian, | NA |
| 5571- | B-Gluc, | immuno, | Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review |
| - | Review, | Var, | NA |
| 5577- | B-Gluc, | Lentinan progress in inflammatory diseases and tumor diseases |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 2769- | Ba, | Rad, | Baicalein ameliorates ionizing radiation-induced injuries by rebalancing gut microbiota and inhibiting apoptosis |
| - | in-vivo, | Nor, | NA |
| 2712- | BBR, | Suppression of colon cancer growth by berberine mediated by the intestinal microbiota and the suppression of DNA methyltransferases (DNMTs) |
| - | in-vitro, | Colon, | HT29 | - | in-vivo, | NA, | NA |
| 2678- | BBR, | Berberine as a Potential Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 5621- | Bif, | immuno, | Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy |
| - | in-vivo, | Var, | NA |
| 5623- | Bif, | Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients |
| - | Study, | NSCLC, | NA |
| 5628- | Bif, | immuno, | Bifidobacterium modulation of tumor immunotherapy and its mechanism |
| - | Review, | Var, | NA |
| 5629- | Bif, | ProBio, | Gut microbiota shapes cancer immunotherapy responses |
| - | Review, | Var, | NA |
| 752- | Bor, | The Potential Role of Boron in the Modulation of Gut Microbiota Composition: An In Vivo Pilot Study |
| - | in-vivo, | CRC, | NA |
| 2776- | Bos, | Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities |
| - | Review, | Var, | NA |
| 8970- | BRice, | Black rice diet alleviates colorectal cancer development through modulating tryptophan metabolism and activating AHR pathway |
| - | Study, | CRC, | NA |
| 5744- | Buty, | PacT, | Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction |
| - | in-vivo, | Var, | NA |
| 5739- | Buty, | Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review) |
| - | Review, | Var, | NA |
| 5735- | Buty, | Butyrate and the Intestinal Epithelium: Modulation of Proliferation and Inflammation in Homeostasis and Disease |
| - | Study, | Nor, | NA |
| 5733- | Buty, | VitB3, | Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis |
| - | in-vivo, | CRC, | NA |
| 5732- | Buty, | GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon |
| - | Study, | CRC, | NA |
| 1032- | Buty, | Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer |
| - | in-vivo, | GC, | AGS |
| 9142- | CC, | immuno, | Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC) |
| - | Trial, | RCC, | NA |
| 9136- | CC, | immuno, | Two Cases of Durable and Deep Responses to Immune Checkpoint Inhibition-Refractory Metastatic Melanoma after Addition of Camu Camu Prebiotic |
| - | Case Report, | Melanoma, | NA |
| 9135- | CC, | A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota |
| - | in-vivo, | Var, | NA |
| 9134- | CC, | Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial |
| - | Trial, | RCC, | NA |
| 6145- | Cin, | Cinnamaldehyde microcapsules enhance bioavailability and regulate intestinal flora in mice |
| - | in-vivo, | Nor, | NA |
| 6164- | Cin, | Advances in pharmacological effects and mechanism of action of cinnamaldehyde |
| - | Review, | Var, | NA | - | Review, | PSA, | NA |
| 6223- | CUR, | Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects |
| - | Review, | Var, | NA |
| 1850- | dietFMD, | Fasting-mimicking diet remodels gut microbiota and suppresses colorectal cancer progression |
| - | in-vivo, | CRC, | NA |
| 1856- | dietFMD, | immuno, | Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review |
| - | Review, | Var, | NA |
| 1863- | dietFMD, | Chemo, | Effect of fasting on cancer: A narrative review of scientific evidence |
| - | Review, | Var, | NA |
| 1844- | dietFMD, | Unlocking the Potential: Caloric Restriction, Caloric Restriction Mimetics, and Their Impact on Cancer Prevention and Treatment |
| - | Review, | Var, | NA |
| 8849- | DIM, | I3C, | Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane |
| - | Review, | Var, | NA |
| 8583- | FS, | The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity |
| - | in-vivo, | BC, | NA |
| - | Trial, | CRC, | NA |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 1038- | Fuc, | immuno, | Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota. |
| - | in-vivo, | BC, | NA |
| 1773- | GA, | Impact of Gallic Acid on Gut Health: Focus on the Gut Microbiome, Immune Response, and Mechanisms of Action |
| - | Review, | Var, | NA |
| 2523- | H2, | Prospects of molecular hydrogen in cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2521- | H2, | Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer |
| - | Review, | CRC, | NA | - | Review, | Lung, | NA | - | Review, | BC, | NA |
| 7652- | IP, | Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation |
| - | in-vivo, | Melanoma, | B16-F10 |
| 7653- | IP, | Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel |
| - | in-vivo, | Var, | NA |
| 7654- | IP, | Dietary Supplementation of Inulin Contributes to the Prevention of Estrogen Receptor-Negative Mammary Cancer by Alteration of Gut Microbial Communities and Epigenetic Regulations |
| - | in-vivo, | BC, | NA |
| - | in-vivo, | BC, | NA |
| 7656- | IP, | Inulin Modulates Gut Microbiota and Increases Short-Chain Fatty Acids Levels to Inhibit Colon Tumorigenesis in Rat Models: A Systematic Review and Meta-Analysis |
| - | Review, | CRC, | NA |
| 7658- | IP, | Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition |
| - | in-vivo, | CRC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:0 prod#:% Target#:350 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid